Antibiotics in IBD: Still a Role in the Biological Era?

Inflammatory Bowel Diseases

Volumn 24, Issue 9, 2018, Pages 1676-1688

  Ledder, Oren ^a,b   Turner, Dan ^a,b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

antibiotics; inflammatory bowel disease

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; GENTAMICIN; METRONIDAZOLE; RIFAXIMIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; CROHN DISEASE; DISEASE SEVERITY; DRUG USE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MAINTENANCE THERAPY; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; REVIEW; ULCERATIVE COLITIS; BACTERIUM; DRUG EFFECT; HOST PATHOGEN INTERACTION; MICROBIOLOGY; PRACTICE GUIDELINE; SECONDARY PREVENTION;

ANTI-BACTERIAL AGENTS; BACTERIA; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION;

EID: 85054917998     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1093/ibd/izy067     Document Type: Review

References (145)

1. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661-73.
2. Su JW, Ma JJ, Zhang HJ. Use of antibiotics in patients with Crohn's disease: A systematic review and meta-analysis. J Dig Dis. 2015;16:58-66.
3. Huang J, Liao C, Wu L, et al. A meta-analysis of randomized controlled trials comparing antibacterial therapy with placebo in Crohn's disease. Colorectal Dis. 2011;13:617-26.
4. Feller M, Huwiler K, Schoepfer A, et al. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010;50:473-80.
5. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52:2920-25.
6. Gupta V, Rodrigues R, Nguyen D, et al. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: A retrospective cohort study and meta-analysis. Aliment Pharmacol Ther. 2016;43:52-60.
7. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105-108.
8. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol. 2011;9:279-90.
9. Flanagan PK, Campbell BJ, Rhodes JM. Lessons from diversion studies and antibacterial interventions. Dig Dis. 2012;30:347-50.
10. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn's colitis. Gut. 1985;26:279-84.
11. Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis. 2006;19:475-84.
12. Jostins L, Ripke S, Weersma RK, et al; International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-24.
13. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-93.
14. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780-85.
15. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731-36.
16. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205-11.
17. Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae. Cell Host Microbe. 2007;2:204.
18. Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol. 2002;97:939-46.
19. Liu Y, van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology. 1995;108:1396-1404.
20. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
21. Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn's disease. Gut. 2017;66:813-22.
22. Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest. 2014;124:3617-33.
23. Kelsen J, Bittinger K, Pauly-Hubbard H, et al. Alterations of the subgingival microbiota in pediatric Crohn's disease studied longitudinally in discovery and validation cohorts. Inflamm Bowel Dis. 2015;21:2797-2805.
24. Lane ER, Zisman TL, Suskind DL. The microbiota in inflammatory bowel disease: current and therapeutic insights. J Inflamm Res. 2017;10:63-73.
25. Scribano ML, Prantera C. Antibiotics and inflammatory bowel diseases. Dig Dis. 2013;31:379-84.
26. Liverani E, Scaioli E, Cardamone C, et al. Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon World J Gastroenterol. 2014;20:13060-70.
27. Subramanian S, Roberts CL, Hart CA, et al. Replication of colonic Crohn's disease mucosal Escherichia coli isolates within macrophages and their susceptibility to antibiotics. Antimicrob Agents Chemother. 2008;52:427-34.
28. Ohkusa T, Sato N, Ogihara T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002;17:849-53.
29. Ohkusa T, Okayasu I, Ogihara T, et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003;52:79-83.
30. Michail S, Durbin M, Turner D, et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis. 2012;18:1799-1808.
31. Gutierrez A, Holler E, Zapater P, et al. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. Inflamm Bowel Dis. 2011;17:1641-50.
32. Gutierrez A, Scharl M, Sempere L, et al. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut. 2014;63:272-80.
33. Chan SS, Watson AJ. Bacterial translocation influences the response to biological therapy in Crohn's disease. Gastroenterology. 2013;145:898-901.
34. Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:651-64.
35. Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: An in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65:2556-65.
36. Gao J, Gillilland MG 3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes. 2014;5:571-75.
37. Rafii F, Ruseler-Van Embden JG, van Lieshout LM. Changes in bacterial enzymes and PCR profiles of fecal bacteria from a patient with ulcerative colitis before and after antimicrobial treatments. Dig Dis Sci. 1999;44:637-42.
38. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:41-62.
39. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-33.
40. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am. 2004;33:335-45, x.
41. Sartor RB. Review article: The potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43(Suppl 1):27-36.
42. Brown CL, Smith K, Wall DM, Walker D. Activity of species-specific antibiotics against Crohn's disease-associated adherent-invasive Escherichia coli. Inflamm Bowel Dis. 2015;21:2372-82.
43. Di Marco R, Mangano K, Quattrocchi C, et al. Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. Clin Immunol. 2003;109:266-71.
44. Wan YC, Li T, Han YD, et al. Effect of pregnane xenobiotic receptor activation on inflammatory bowel disease treated with rifaximin. J Biol Regul Homeost Agents. 2015;29:401-10.
45. Kolios G, Manousou P, Bourikas L, et al. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur J Clin Invest. 2006;36:720-29.
46. Dogan B, Scherl E, Bosworth B, et al. Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. Inflamm Bowel Dis. 2013;19:141-50.
47. Beckler DR, Elwasila S, Ghobrial G, et al. Correlation between rpob gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease. World J Gastroenterol. 2008;14:2723-30.
48. Gomollon F, Dignass A, Annese V, et al; ECCO. 3rd European evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3-25.
49. Selby W, Pavli P, Crotty B, et al; Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology. 2007;132:2313-19.
50. Chamberlin W. Importance of the Australian Crohn's Disease Antibiotic Study. Gastroenterology. 2007;133:1744-5; author reply 1745.
51. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328-32.
52. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23:1117-25.
53. Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol. 1994;89:513-18.
54. Prantera C, Lochs H, Grimaldi M, et al; Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology. 2012;142:473-481. e4.
55. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology. 2002;123:33-40.
56. Graham D. Prolonged remission in CD following treatment for Mycobacterium paratuberculosis. Gastroenterology. 1995;108:A826.
57. Leiper K, Martin K, Ellis A, et al. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther. 2008;27:1233-39.
58. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071-75.
59. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis. 2002;8:10-15.
60. Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci. 1991;36:449-53.
61. Goodgame RW, Kimball K, Akram S, et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther. 2001;15:1861-66.
62. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:778-88.
63. Hoekman DR, Zeevenhooven J, D'Haens GR, Benninga MA. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. Eur J Gastroenterol Hepatol. 2017;29:1086-90.
64. Ricci JEJ, Chebli LA, Ribeiro TC, et al. Small-intestinal bacterial overgrowth is associated with concurrent intestinal inflammation but not with systemic inflammation in Crohn's disease patients. J Clin Gastroenterol. 2017; doi:10. 1097/ MCG. 0000000000000803.
65. Cash BD. Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome. Curr Med Res Opin. 2014;30:1405-15.
66. Levine A, Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. J Crohns Colitis. 2011;5:222-26.
67. Chamberlin W, Ghobrial G, Chehtane M, Naser SA. Successful treatment of a Crohn's disease patient infected with bacteremic Mycobacterium paratuberculosis. Am J Gastroenterol. 2007;102:689-91.
68. Elliott PR, Moore GT, Bell SJ, Connell WR. Severe recurrent Crohn's disease of the ileocolonic anastomosis disappearing completely with antibacterial therapy. Gut. 2005;54:1818-19.
69. Shafran I, Kugler L, El-Zaatari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis. 2002;34:22-28.
70. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin. 2005;21:1165-69.
71. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther. 2000;14:801-806.
72. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol. 1998;12:53-56.
73. Gui GP, Thomas PR, Tizard ML, et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother. 1997;39:393-400.
74. Hampson SJ, Parker MC, Saverymuttu SH, et al. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther. 1989;3:343-52.
75. Levine A, Kori M, Kierkus J, et al. Azithromycin versus metronidazole based therapy for induction of remission in mild to moderate paediatric Crohn's disease: A randomized controlled trial. Gut. 2018; doi:10. 1136/gutjnl-2017-315199.
76. Aberra FN, Brensinger CM, Bilker WB, et al. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005;3:459-65.
77. Sokol H. Probiotics and antibiotics in IBD. Dig Dis. 2014;32(Suppl 1):10-17.
78. Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn's disease. World J Gastroenterol. 2014;20:1147-54.
79. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617-21.
80. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856-61.
81. Manosa M, Cabre E, Bernal I, et al. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: A randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis. 2013;19:1889-95.
82. Herfarth HH, Katz JA, Hanauer SB, et al. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: A randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013;19:1073-79.
83. Campieri M. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study versus mesalazine. Gastroenterology. 2000;118:A781.
84. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009:CD006873.
85. Rutgeerts P, Geboes K, Vantrappen G, et al. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol. 1992;15:24-28.
86. Sorrentino D. State-of-the-art medical prevention of postoperative recurrence of Crohn's disease. Nat Rev Gastroenterol Hepatol. 2013;10:413-22.
87. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: A randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15:17-24.
88. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: A double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329-36.
89. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: A randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292-99.
90. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003;18:1113-1120.
91. Panes J, Rimola J. Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652-64.
92. Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44:1220-21.
93. Dickinson RJ, O'Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26:1380-84.
94. Burke DA, Axon AT, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990;4:123-29.
95. Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115:1072-78.
96. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994;89:43-46.
97. Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001;36:971-74.
98. Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol. 1997;92:454-56.
99. Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: A randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol. 2005;40:1334-42.
100. Ohkusa T, Kato K, Terao S, et al; Japan UC Antibiotic Therapy Study Group. Newly developed antibiotic combination therapy for ulcerative colitis: A double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820-29.
101. Petersen AM, MIRsepasi H, Halkj. r SI, et al. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J Crohns Colitis. 2014;8:1498-1505.
102. Burke DA, Axon AT, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990;4:123-29.
103. Terao S, Yamashiro K, Tamura I, et al. Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis. Digestion. 2011;83:198-203.
104. Turner D, Levine A, Kolho KL, et al. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report. J Crohns Colitis. 2014;8:1464-70.
105. Kato K, Ohkusa T, Terao S, et al. Adjunct antibiotic combination therapy for steroid-refractory or-dependent ulcerative colitis: An open-label multicentre study. Aliment Pharmacol Ther. 2014;39:949-56.
106. Uehara T, Kato K, Ohkusa T, et al. Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. J Gastroenterol Hepatol. 2010;25(Suppl 1):S62-S66.
107. Peppercorn MA. Are antibiotics useful in the management of nontoxic severe ulcerative colitis J Clin Gastroenterol. 1993;17:14-17.
108. Turner D, Vlamakis H, Marcus D, et al. Manipulating the microbiome in pediatric acute severe colitis with antibiotics cocktail: A pilot randomized controlled trial. Paper presented at: ESPGHAN 51st Annual meeting; Geneva, Switzerland, May 9-12, 2018.
109. Lev-Tzion R, Ledder O, Shteyer E, et al. Oral vancomycin and gentamicin for treatment of very early onset inflammatory bowel disease. Digestion. 2017;95:310-13.
110. Uhlig HH, Schwerd T, Koletzko S, et al; COLORS in IBD Study Group and NEOPICS. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990-1007. e3.
111. Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther. 1993;7:155-58.
112. Nguyen GC. Tip of the iceberg The emergence of antibiotic-resistant organisms in the IBD population. Gut Microbes. 2012;3:434-36.
113. Leung W, Malhi G, Willey BM, et al. Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population. J Crohns Colitis. 2012;6:743-49.
114. Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host Microbe. 2015;18:489-500.
115. Yassour M, Vatanen T, Siljander H, et al; DIABIMMUNE Study Group. Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med. 2016;8:343ra81.
116. Sonoda A, Sachi N, Gendo Y, et al. A combined administration of ampicillin and vancomycin induces mild colitis with decreased diversity of gut microbiota and pertubation of glutamine and short chain fatty acid metabolisms. Unit Eur Gastroenterol J. United European Gastroenterology Journal 2017;5 (Supplement 1).
117. Swidsinski A, Loening-Baucke V, Bengmark S, et al. Bacterial biofilm suppression with antibiotics for ulcerative and indeterminate colitis: consequences of aggressive treatment. Arch Med Res. 2008;39:198-204.
118. Zeitz J, Fournier N, Labenz C, et al. Risk factors for the development of fistulae and stenoses in Crohn's disease patients in the Swiss Inflammatory Bowel Disease Cohort. Inflmmatory Intestinal Diseases. 2016;1:172-81.
119. Drouet M, Vignal C, Singer E, et al. AIEC colonization and pathogenicity: influence of previous antibiotic treatment and preexisting inflammation. Inflamm Bowel Dis. 2012;18:1923-31.
120. Small CL, Reid-Yu SA, McPhee JB, Coombes BK. Persistent infection with Crohn's disease-associated adherent-invasive Escherichia coli leads to chronic inflammation and intestinal fibrosis. Nat Commun. 2013;4:1957.
121. Li WQ, Cho E, Khalili H, et al. Rosacea, use of tetracycline, and risk of incident inflammatory bowel disease in women. Clin Gastroenterol Hepatol. 2016;14:220-5e1
122. Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: A meta-analysis. Am J Gastroenterol. 2014;109:1728-38.
123. Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: A population-based cohort study. Pediatrics. 2012;130:e794-e803.
124. Virta L, Auvinen A, Helenius H, et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease-A nationwide, register-based Finnish case-control study. Am J Epidemiol. 2012;175:775-84.
125. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2011;106:2133-42.
126. Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60:49-54.
127. Card T, Logan RF, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn's disease. Gut. 2004;53:246-50.
128. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010;105:2687-92.
129. Aniwan S, Tremaine WJ, Raffals LE, et al. Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota: A population-based case-control study. J Crohns Colitis. 2018;12(2):137-44.
130. De Vroey B, De Cassan C, Gower-Rousseau C, Colombel JF. Editorial: Antibiotics earlier, IBD later Am J Gastroenterol. 2010;105:2693-96.
131. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. 2006;130:1588-94.
132. Porter CK, Tribble DR, Aliaga PA, et al. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology. 2008;135:781-86.
133. Gradel KO, Nielsen HL, Schonheyder HC, et al. Increased short-and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009;137:495-501.
134. Kalischuk LD, Inglis GD, Buret AG. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog. 2009;1:2.
135. Kalischuk LD, Buret AG. A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease Am J Physiol Gastrointest Liver Physiol. 2010;298:G1-G9.
136. Nguyen GC. Editorial: bugs and drugs: insights into the pathogenesis of inflammatory bowel disease. Am J Gastroenterol. 2011;106:2143-45.
137. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology. 2011;140:1729-37.
138. Henckaerts L, Nielsen KR, Steffensen R, et al. Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med. 2009;37:192-201, e1.
139. Roy A, Lichtiger S. Clostridium difficile infection: A rarity in patients receiving chronic antibiotic treatment for Crohn's disease. Inflamm Bowel Dis. 2016;22:648-53.
140. Ruemmele FM, Veres G, Kolho KL, et al; European Crohn's and Colitis Organisation; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8:1179-1207.
141. Huffnagle GB, Noverr MC. The emerging world of the fungal microbiome. Trends Microbiol. 2013;21:334-41.
142. Babickova J, Gardlik R. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World J Gastroenterol. 2015;21:11321-30.
143. Mukhopadhya I, Hansen R, Meharg C, et al. The fungal microbiota of de-novo paediatric inflammatory bowel disease. Microbes Infect. 2015;17:304-10.
144. Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005;11(Suppl 1):S3-12.
145. Greenberg GR. Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis. 2004;10:318-20.